Company Profiles

driven by the PitchBook Platform

Arecor

Arecor
2007 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
Later Stage VC LATEST DEAL TYPE
$77K LATEST DEAL AMOUNT
8 INVESTORS
Description

Provider of technology designed to prevent the degradation of proteins and vaccines during storage. The company's technology enhance the commercial value and practical utility of many types of proteins and applications, which include vaccines and therapeutic proteins, enabling healthcare providers to improve the treatment of diabetes care via the innovative reformulation of approved proteins and peptides.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Enterprise Systems (Healthcare)
Primary Office
  • Chesterford Research Park
  • Little Chesterford CB10 1XL
  • England

+44 01223 000000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Arecor’s full profile, request a free trial.

Arecor Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC 20-Feb-2017 $77K 00.000 000.00 Completed Generating Revenue
10. Grant 01-Feb-2017 00.000 00.00 Completed Generating Revenue
9. Later Stage VC (Series A2) 22-Apr-2013 00.000 00.00 000.00 Completed Generating Revenue
8. Grant 06-Nov-2012 00.000 00.000 Completed Generating Revenue
7. Grant 00.000 Completed Generating Revenue
6. Later Stage VC (Series A2) 06-Sep-2012 00000 00.000 00.00 Completed Generating Revenue
5. Later Stage VC (Series A2) 24-Feb-2012 00000 00.000 00.000 Completed Generating Revenue
4. Early Stage VC (Series A2) 01-May-2011 00.000 00.000 00.000 Completed Startup
3. Early Stage VC (Series A1) 30-Mar-2010 00.000 00.00 00.000 Completed Startup
2. Early Stage VC (Series A1) 01-Jan-2009 $434K $1.64M 00.000 Completed Startup
1. Early Stage VC (Series A1) 01-Jul-2007 $1.21M $1.21M 00.000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Arecor Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A2 000,000 00.000000 00.00 00.00 00 00.00 00.000
B1 Ordinary 00,000 00.000000 00.00 00.00 00 00.00 0.00
Series A3 000,000 00.000000 00.00 00.00 00 00.00 0.000
B Ordinary 9,250 $0.012485 $4.99 $4.99 1x $4.99 0.57%
Series A1 696,203 $0.012485 $3.58 $3.58 1x $3.58 42.87%
To view this company’s complete Cap Table, request access »

Arecor Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
O2h Ventures Venture Capital Minority 000 0000 000000 0
Innovate UK Accelerator/Incubator 000 0000 000000 0
Cambridge Capital Group Angel Group Minority 000 0000 000000 0
DSM Apps Corporation Minority 000 0000 000000 0
DSM Venturing Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Arecor Executive Team (4)

Name Title Board
Seat
Contact
Info
Sarah Howell Ph.D Chief Executive Officer & Board Member
Jan Jezek Ph.D Chief Scientific Officer
David Gerring Head of Development

1 Former Executive

You’re viewing 3 of 4 executives. Get the full list »

Arecor Board Members (8)

Name Representing Role Since Contact
Info
Alan Smith Ph.D Self Board Member 000 0000
Andrew Lane Unilever Ventures Chairman 000 0000
Andrew Richards Ph.D Self Board Member 000 0000
Ian Freelance DSM Venturing Board Member 000 0000
Sarah Howell Ph.D Arecor Chief Executive Officer & Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 8 board members. Get the full list »